aTyr Pharma (NASDAQ:ATYR) Upgraded by Freedom Capital to “Strong-Buy” Rating

Posted by on May 21st, 2026

aTyr Pharma (NASDAQ:ATYR – Get Free Report) was upgraded by stock analysts at Freedom Capital from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Other analysts also recently issued reports about the stock. Wall Street Zen upgraded shares of aTyr Pharma from a “sell” rating to a “hold” rating in a report on Sunday. Jefferies Financial Group restated a “buy” rating on shares of aTyr Pharma in a report on Friday, March 6th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $25.67.

Check Out Our Latest Analysis on aTyr Pharma

aTyr Pharma Stock Performance

NASDAQ ATYR opened at $0.53 on Wednesday. The business has a 50 day simple moving average of $0.79 and a 200 day simple moving average of $0.80. aTyr Pharma has a 52-week low of $0.40 and a 52-week high of $7.29. The stock has a market cap of $52.03 million, a price-to-earnings ratio of -0.73 and a beta of 0.66.

aTyr Pharma (NASDAQ:ATYR – Get Free Report) last announced its earnings results on Friday, May 15th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.05. On average, analysts predict that aTyr Pharma will post -0.66 EPS for the current year.

Institutional Trading of aTyr Pharma

Large investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System bought a new stake in shares of aTyr Pharma in the 2nd quarter valued at about $28,000. Main Street Financial Solutions LLC increased its position in aTyr Pharma by 7.0% during the second quarter. Main Street Financial Solutions LLC now owns 143,600 shares of the company’s stock worth $728,000 after buying an additional 9,350 shares during the last quarter. Legal & General Group Plc bought a new stake in aTyr Pharma in the second quarter valued at approximately $49,000. Raymond James Financial Inc. raised its stake in aTyr Pharma by 79.3% in the second quarter. Raymond James Financial Inc. now owns 24,839 shares of the company’s stock valued at $126,000 after buying an additional 10,989 shares during the period. Finally, Prudential Financial Inc. acquired a new stake in shares of aTyr Pharma in the second quarter valued at approximately $63,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

About aTyr Pharma

(Get Free Report)

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.

Featured Articles

Analyst Recommendations for aTyr Pharma (NASDAQ:ATYR)

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.